從一線(xiàn)至后線(xiàn)的精準(zhǔn)管理新紀(jì)元，埃萬(wàn)妥單抗重塑EGFR突變晚期NSCLC治療版圖

EGFR突變NSCLC治療格局已被改寫(xiě)，開(kāi)啟長(zhǎng)生存時(shí)代。

*以下內(nèi)容僅供醫(yī)療衛(wèi)生專(zhuān)業(yè)人士瀏覽。

參考文獻(xiàn)：

[1] Cho BC, Lu S, Felip E, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498.

[2]Cho BC, Lu S, Felip E, et al. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025 Sep 7.

[3]Lu S, et al. Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis. 2023 ESMO Asia. LBA10.

[4]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines?) Non-Small Cell Lung Cancer. Version 2. 2026.

[5]中國(guó)臨床腫瘤學(xué)會(huì)（CSCO）非小細(xì)胞肺癌診療指南（2025年）.

[6]Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77-90.

[7]Shih JY, Wang J, Wang Y, et al. Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis. 2023 ESMO Asia. LBA11.

[8]Califano R, Passaro A, Tan JL, et al. Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2. 2025 ASCO. Abstract 8639.

[9]Reck M, et al. Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-mutant Advanced NSCLC After Progression on Osimertinib: A Post-progression Analysis of MARIPOSA-2. ELCC Congress 2024, 3MO.

[10]Zhou CC, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051.

[11]Zhou CC, Tang KJ, Liu B, et al. Amivantamab Plus Chemotherapy vs Chemotherapy as a First-line Treatment Among Asian Patients With EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): PAPILLON Subgroup Analysis. 2023 ESMO Asia. 513MO.

[12]Felip E, Shu C, Aguilar A, et al. Amivantamab Plus Chemotherapy vs Chemotherapy as First-Line Treatment in EGFR Exon 20 Insertion–mutated Advanced NSCLC: Analysis of PostProgression Endpoints From PAPILLON. 2024 ELCC. 2MO.

審批編碼：CP-558510

批準(zhǔn)分發(fā)日期：12/18/2025

有效期：12/18/2026

*“醫(yī)學(xué)界”力求所發(fā)表內(nèi)容專(zhuān)業(yè)、可靠，但不對(duì)內(nèi)容的準(zhǔn)確性做出承諾；請(qǐng)相關(guān)各方在采用或以此作為決策依據(jù)時(shí)另行核查。